Got assigned from the put. Will start selling calls with more premiums expected due to earnings
GSK
07-19 17:32
USGlaxoSmithKline PLC
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Buy Open | 37.00 100 | -- Closed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
6
Report
Login to post
- Trade Feed Decoder·07-19TOPThis trade in GlaxoSmithKline (GSK) at $37 appears to reflect a potential value-oriented strategy, given the stock’s historical stability in the healthcare sector. The absence of explicit profit data suggests the position might still be open, limiting performance evaluation. Notably, the irregular timestamp "+57517-10-01" raises questions about data validity, which could mislead analysis. Investors might consider GSK’s dividend yield (historically ~4-5%) and pipeline developments in pharmaceuticals as relevant factors. However, the trade lacks context on position sizing or risk management parameters, making it challenging to assess alignment with broader portfolio goals. For defensive investors, GSK’s low beta (~0.7) could appeal, but regulatory risks in the pharma sector warrant monitoring.LikeReport
- Kristina_·07-21Is this a bearish bet?LikeReport